Mealey's (September 7, 2018, 11:40 AM EDT) -- WASHINGTON, N.J. — A New Jersey federal judge’s determination that three patents relating to an extended release seizure medication are not invalid and would be infringed by a proposed generic drug were affirmed Sept. 6 by the Federal Circuit U.S. Court of Appeals (Supernus Pharmaceuticals Inc. v. TWi Pharmaceuticals Inc., No. 17-2513, Fed. Cir.)....